Breaking Through

Adaptin Bio, is a pioneering biotechnology company dedicated to revolutionizing drug delivery. Our focus is on developing innovative technologies that enhance how medications and other therapeutic compounds reach their target destinations within the body.

Our core mission is to overcome a major hurdle in medicine: ensuring effective delivery of drugs to specific tissues.

Many critical medications and diagnostic tools struggle to reach the areas where they can have the most significant impact. The blood-brain barrier that protects the central nervous system being the most famous example.

Adaptin Bio’s precision medicine technologies are designed to address this challenge. We are creating methods to deliver drugs and other compounds directly to their target sites, maximizing their effectiveness and minimizing potential side effects.

Area of Expertise

Blood-Brain Barrier Delivery: Our flagship technology, BRiTE (Brain Bispecific T Cell Engager), tackles the challenge of transporting T cell therapies across the blood-brain barrier. This allows these powerful immune system fighters to reach and eliminate malignant tumors within the brain.

Lead Product

APTN-101:
This is a proprietary BRiTE therapeutic designed to target EGFRvIII, a specific protein associated with aggressive brain tumors. Preclinical studies show significant promise for APTN-101 in eliminating these tumors. We are actively working towards our first human trial.

Our Vision

Adaptin Bio is committed to developing a new generation of targeted therapies. By overcoming delivery barriers, we aim to unlock the full potential of existing and future medications, leading to improved patient outcomes across a wide range of diseases.